Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II BEXE/BEXET metronomic chemotherapy in advanced breast cancer
2007-006025-27Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Feb 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, capecitabine, bevacizumab, erlotinib and trastuzumab in breast cancer, sponsored by European Institute of Oncology. Primary endpoints: Overall clinical benefit and Toxicity profile. Started Feb 2008; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-006025-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006025-27.